Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation

NCT07566299 is registered in ClinicalTrials.gov with Chung Shan Medical University as lead sponsor.

NCT NCT07566299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07566299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation
Lead sponsor
Chung Shan Medical University
Phase
Observational
Overall status
Completed
Start date
January 1, 2017
Completion date
March 31, 2026
Enrollment
118,805 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular-kidney-metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, obesity type 2 diabetes mellitus